Approval · Notice of Compliance 28657 · 2022
CONSTELLA: Notice of Compliance 28657
Issued July 26, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28657
- Date
- July 26, 2022
- Company
- Allergan IncMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph (PM) with safety information from a new study conducted in lactating women and to update the PM to the 2020 Master Template
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CONSTELLA | Not yet assigned | — |
Medicinal ingredients
- LINACLOTIDE 72 MCG per CAP
- LINACLOTIDE 145 MCG per CAP
- LINACLOTIDE 230 MCG per CAP